{"id":52412,"date":"2026-01-09T02:19:38","date_gmt":"2026-01-09T01:19:38","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/01\/09\/phase-ii-trial-of-interleukin-12-followed-by-interferon-alfa-2b-in-patients-with-metastatic-malignant-melanoma-results-from-calgb-500001-alliance\/"},"modified":"2026-01-09T02:19:38","modified_gmt":"2026-01-09T01:19:38","slug":"phase-ii-trial-of-interleukin-12-followed-by-interferon-alfa-2b-in-patients-with-metastatic-malignant-melanoma-results-from-calgb-500001-alliance","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/01\/09\/phase-ii-trial-of-interleukin-12-followed-by-interferon-alfa-2b-in-patients-with-metastatic-malignant-melanoma-results-from-calgb-500001-alliance\/","title":{"rendered":"Phase II trial of interleukin-12 followed by interferon alfa-2b in patients with metastatic malignant melanoma: Results from CALGB 500001 (Alliance)"},"content":{"rendered":"
\n

Cancer Immunol Res<\/b>. 2026 Jan 8. doi: 10.1158\/2326-6066.CIR-25-0880. Online ahead of print.<\/p>\n

ABSTRACT<\/b><\/p>\n

The ability of interleukin-12 (IL-12) to stimulate production of interferon gamma (IFN-\u03b3) suggested it might improve the efficacy of low dose interferon alpha (IFN-\u03b1). In this phase II trial, patients with metastatic malignant melanoma were administered recombinant human (rh) IL-12 followed by IFN-\u03b12b. Primary endpoints were clinical response and progression-free survival. Secondary objectives were to evaluate the effect of endogenous IFN-\u03b3 on JAK-STAT signaling and IFN-regulated genes in peripheral blood mononuclear cells (PBMCs). Patients with advanced melanoma received rhIL-12 on day 1 and IFN-\u03b12b on days 2-6 of a 14-day cycle. rhIL-12 was given intravenously at 300 ng\/kg. IFN \u03b12b was dosed at 3\u00d7106 units subcutaneously. Plasma IFN-\u03b3 was assayed by ELISA; JAK-STAT signaling was measured in PBMCs by flow cytometry. The proportion of responders was assessed via Simon’s two-stage design. Thirty-eight patients were enrolled. The regimen was well-tolerated. Two patients achieved a partial response lasting 6 months or longer (5.3%). IL-12 administration led to an increase in mean plasma IFN-\u03b3 from 33.57 pg\/mL at baseline to a maximum of 564.86 pg\/mL and increased expression of STAT1 and STAT2 in PBMCs. Generation of phosphorylated STAT1 and interferon-simulated gene product 15 in response to IFN-\u03b1 was enhanced following IL-12. rhIL-12 given prior to IFN-\u03b12b stimulated production of IFN \u03b3, which led to increased levels of JAK-STAT signaling intermediates in patient PBMCs. Combination therapy was reasonably well-tolerated but conferred marginal benefit in patients with metastatic melanoma. These results can inform future studies that employ recombinant IL-12 or novel IL-12 constructs.<\/p>\n

PMID:41505731<\/a> | DOI:10.1158\/2326-6066.CIR-25-0880<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Cancer Immunol Res. 2026 Jan 8. doi: 10.1158\/2326-6066.CIR-25-0880. Online ahead of print. ABSTRACT The ability of interleukin-12 (IL-12) to stimulate production of interferon gamma (IFN-\u03b3) suggested it might improve the efficacy of low dose interferon alpha (IFN-\u03b1). In this phase II trial, patients with metastatic malignant melanoma were administered recombinant human (rh) IL-12 followed by … Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-52412","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/52412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=52412"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/52412\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=52412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=52412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=52412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}